We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials.
- Authors
Sun, Rui; Bustamante, Mercedes; Gurusamy, Venkatesh Kumar; Lebwohl, Mark; Gottlieb, Alice B.; Mease, Philip J.; Deodhar, Atul; Bao, Weibin; Mendelson, Meryl; Porter, Brian; Chand, Deepa; Dong, Victor
- Abstract
Introduction: Secukinumab is an anti-interleukin (IL)-17A monoclonal antibody indicated for multiple immunological disorders. Here, we aim to summarize secukinumab safety in clinical trials (CTs) and post-marketing setting (PMS) until 25 June 2022. Methods: Adverse events (AEs) were summarized with crude reporting rate (RR) per 100 patient-years (PY) in PMS for all reported indications and with exposure-adjusted incident rates (EAIR) per 100 PY in pooled 47 CTs for approved indications. Results: Secukinumab exposure totaled 1,159,260 PY in PMS and 27,765 PY in CTs. AEs were mostly (> 80%) non-serious in PMS. EAIR for serious AEs was 7.0/100 PY. Nasopharyngitis (RR 0.59/100 PY, EAIR 16.08/100 PY) and pneumonia (RR 0.14/100 PY, EAIR 0.17/100 PY) were the most common infection and serious infection, respectively. Candida infections (RR 0.20/100 PY, EAIR 2.16/100 PY) were the most common fungal infections. Inflammatory bowel disease (IBD) was observed in PMS (0.14/100 PY) and CTs (0.26/100 PY). Most (76%) patients with prior IBD did not report IBD flare during CTs. PMS monitoring identified paradoxical skin reactions including dyshidrotic eczema (RR 0.006/100 PY) and pyoderma gangrenosum (RR 0.003/100 PY). Conclusion: Secukinumab safety profile with increased patient exposure remained favorable. Paradoxical skin reactions were identified in post-marketing monitoring.
- Subjects
CLINICAL trials; INFLAMMATORY bowel diseases; CANDIDIASIS; MYCOSES; PYODERMA gangrenosum
- Publication
Dermatology & Therapy, 2024, Vol 14, Issue 3, p729
- ISSN
2193-8210
- Publication type
Article
- DOI
10.1007/s13555-024-01122-2